GlassScriptPhysician profile
Ala'A Mitoubsi
NPI 1841915113
$3,300.13
in general payments reported to CMS, 2019-2025
35 companies · $609 in 2025
The $609 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $187 · 2023: $1,969 · 2024: $536 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,844 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,844.44 |
| Education | $268.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $523.34 | 2022-2025 | Rybrevant, Akeega, Talvey |
| Seagen INC. | $378.11 | 2023-2025 | Adcetris, Tukysa |
| Celgene Corporation | $372.38 | 2023-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $299.41 | 2023-2025 | Kisqali |
| E.R. Squibb & Sons, L.L.C. | $219.62 | 2023-2024 | Opdivo, Opdualag, Pomalyst |
| Incyte Corporation | $170.25 | 2023-2024 | Jakafi |
| Glaxosmithkline, LLC. | $144.23 | 2023-2024 | Ojjaara |
| Astrazeneca Pharmaceuticals LP | $142.78 | 2023-2024 | Tagrisso, Enhertu |
| Genentech USA, INC. | $112.38 | 2023-2025 | Tecentriq, Rozlytrek, Alecensa |
| Exelixis INC. | $86.12 | 2023-2024 | Cabometyx |
| Mirati Therapeutics, INC. | $66.56 | 2023 | Krazati |
| Aveo Pharmaceuticals, INC. | $62.33 | 2023 | Fotivda |
| Rigel Pharmaceuticals, INC. | $59.29 | 2023-2024 | Tavalisse, Rezlidhia |
| Pfizer INC. | $57.40 | 2024-2025 | |
| Genmab U.S., INC. | $49.55 | 2023-2024 | Epkinly |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $48.31 | 2023 | |
| Lilly USA, LLC | $43.87 | 2023-2024 | Retevmo, Jaypirca, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $43.71 | 2023 | |
| Abbvie INC. | $41.73 | 2025 | |
| Daiichi Sankyo INC. | $41.59 | 2025 | Vanflyta, Enhertu |
| Amgen INC. | $36.57 | 2023 | Kyprolis, Lumakras |
| Springworks Therapeutics, INC. | $31.70 | 2025 | Ogsiveo |
| Astellas Pharma US INC | $27.81 | 2025 | Cresemba |
| Alexion Pharmaceuticals, INC. | $27.44 | 2023 | Ultomiris |
| Sobi, INC | $25.10 | 2025 | |
| Macrogenics, INC. | $23.23 | 2022 | |
| Caris Mpi, INC. | $23.00 | 2025 | Mi Cancer Seek |
| Kyowa Kirin, INC. | $22.69 | 2023 | Poteligeo |
| Merck Sharp & Dohme LLC | $20.76 | 2022 | |
| Eisai INC. | $20.26 | 2023 | |
| Tempus Ai, INC | $19.80 | 2025 | Xt Cdx |
| Pharmacosmos Therapeutics INC. | $16.56 | 2023 | Monoferric |
| Taiho Oncology, INC. | $14.24 | 2023 | |
| Aadi Bioscience, INC. | $14.02 | 2023 | Fyarro |
| Coherus Oncology, INC. | $13.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ala'A Mitoubsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.